Search Results
Your search for ,foR matches 32418 pages
Showing 22551 - 22600AACR 2016: Genomic Variants May Influence Risk for Breast Cancer After Chest Radiotherapy to Treat Childhood Cancer
Among females who received radiotherapy to the chest as part of treatment for a childhood cancer, those who had either of two specific genetic variants were at significantly higher risk of developing breast cancer later in life, according to research presented by Morton et al at the 2016 AACR...
AACR 2016: Cologuard Detected Colorectal Cancer in Previously Unscreened Patients
A noninvasive colorectal cancer-screening test detected the disease in patients who had previously avoided more invasive screening measures, according to research presented by Prince et al at the 2016 AACR Annual Meeting (Abstract LB-296). The study of nearly 400 patients revealed four patients...
KIR3DL1 and HLA-B Allele Combinations May Impact Response to Treatment in Neuroblastoma
In a study reported in the Journal of Clinical Oncology, Forlenza et al found that noninteracting KIR3DL1 and HLA-B subtypes were associated with better response to anti-GD2 antibody treatment in neuroblastoma. Study Details Treatment of neuroblastoma with anti-GD2 monoclonal antibody (eg, the...
AACR 2016: Nivolumab Improved Survival for Patients With Head and Neck Squamous Cell Carcinoma
For the latest information on CheckMate-141, click here, here, or here. Treatment with the immunotherapeutic nivolumab (Opdivo) improved survival for patients with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy compared with...
Adjuvant Trastuzumab May Be Insufficiently Used in Older Women With Breast Cancer
Reeder-Hayes et al found that adjuvant trastuzumab (Herceptin) may be underused in older women with early-stage HER2-positive breast cancer and reported their study results in the Journal of Clinical Oncology. Adjuvant trastuzumab also was used less often in black women than in white women. Rates...
Boswellia
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. We chose Boswellia for this issue because of its increasing use by patients with cancer....
Blue Ribbon Panel to Help Guide National Cancer Moonshot Initiative
On April 4, 2016, The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), announced a Blue Ribbon Panel of scientific experts, cancer leaders, and patient advocates that will inform the scientific direction and goals at NCI of Vice President Joe Biden’s National Cancer ...
Scott A. Armstrong, MD, PhD, to Lead Department of Pediatric Oncology at Dana-Farber Cancer Institute
Scott A. Armstrong, MD, PhD, has been named Chair of the Department of Pediatric Oncology at Dana-Farber Cancer Institute and the David G. Nathan Professor of Pediatrics at Dana-Farber Cancer Institute, Boston Children’s Hospital, and Harvard Medical School. He will also serve as Associate Chief of ...
Expert Point of View: Thierry Facon, MD
Thierry Facon, MD, of Lille University Hospital in France, told The ASCO Post that he believes elotuzumab (Empliciti) works better with an immunomodulatory drug than with bortezomib (Velcade), at least according to the results of these two studies. “I think what’s most impressive is the ELOQUENT-2 ...
Updates on Elotuzumab in Multiple Myeloma Show Persistence of Benefit
Studies presented at the 2015 ASH Annual Meeting bolstered support for elotuzumab (Empliciti) given in combination with lenalidomide (Revlimid) for the treatment of multiple myeloma. Elotuzumab is an immunostimulatory monoclonal antibody. It has a dual mechanism of action, directly activating...
Expert Point of View: Thierry Facon, MD
Thierry Facon, MD, of Lille University Hospital in France, spoke to The ASCO Post about the preliminary results of the pembrolizumab studies. Dr. Facon cautioned that a response rate of 76% overall “is not so impressive,” given about 65% of patients respond to lenalidomide/dexamethasone alone....
Pembrolizumab Looks Promising in Multiple Myeloma
Monoclonal antibodies targeting the programmed cell death protein (PD-1) receptor look promising in multiple myeloma, according to early reports presented at the 2015 ASH Annual Meeting and Exposition. Early signs of activity in heavily pretreated patients may indicate that, as in solid tumors,...
Active Surveillance Has Become Standard Care for Men With Low-Risk Localized Prostate Cancer
Active surveillance has been increasingly adopted as a standard approach for men with Gleason score ≤ 6 localized prostate cancer, with major guidelines and consensus statements encouraging this approach,1 including a recently published guideline from Cancer Care Ontario (CCO),2 and endorsement of...
DigniCap Scalp-Cooling System Now Available for Women With Breast Cancer at 10 U.S. Cancer Treatment Centers
Dignitana Inc. recently announced that the DigniCap scalp cooling system, which was cleared by the U.S. Food and Drug Administration (FDA) in December 2015 to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, is now available at 10 cancer treatment...
ASCO Endorses Cancer Care Ontario Guideline on Active Surveillance for Management of Localized Prostate Cancer
As reported by Ronald C. Chen, MD, MPH, of the University of North Carolina at Chapel Hill, and colleagues in the Journal of Clinical Oncology, ASCO has endorsed, with qualifications, the 2015 Cancer Care Ontario (CCO) guideline on active surveillance for management of localized prostate cancer....
Michael A. Caligiuri, MD, Named AACR President-Elect 2016–2017
The members of the American Association for Cancer Research (AACR) have elected Michael A. Caligiuri, MD, as their President-Elect for 2016–2017. He officially became President-Elect at the AACR Annual Meeting 2016, held in New Orleans, April 16–20, and will assume the presidency in April 2017 at...
CDX2 in Stage II Colon Cancer: Ready for Prime Time?
In a recent issue of The New England Journal of Medicine, Dalerba et al published an impressive article describing a novel bioinformatics approach to identifying new prognostic and predictive biomarkers in patients with stage II and III colon cancer (see summary in this issue of The ASCO Post).1...
City of Hope Awarded NCI Research Grant for Potential Acute Myeloid Leukemia Drug
A City of Hope research team led by Steven T. Rosen, MD, City of Hope’s Provost and Chief Scientific Officer, has been awarded a $2.3 million Research Project Grant (R01) from the National Cancer Institute (NCI) to fund studies associated with a phase I/II clinical trial in relapsed/refractory...
Transcription Factor CDX2 May Be a Prognostic Biomarker in Stage II and III Colon Cancer
In a study reported in The New England Journal of Medicine, Piero Dalerba, MD, of Columbia University, and colleagues found that absence of the transcription factor CDX2 was prognostic for poor outcome in patients with stage II and III colon cancer vs cancers with CDX2 expression.1 However,...
Neoadjuvant Endocrine Therapy Vastly Underutilized by U.S. Clinicians
Neoadjuvant endocrine therapy in the management of breast cancer is woefully underutilized by U.S. clinicians, according to advocates of this approach who made their case at the 2016 Miami Breast Cancer Conference.1 In postmenopausal women with estrogen receptor–rich tumors, neoadjuvant endocrine...
Expert Point of View: Patrick Borgen, MD
Patrick Borgen, MD, Chair of the Department of Surgery at Maimonides Medical Center, Brooklyn, New York, called these findings important and clinically relevant. “This study was an enormous undertaking, to review the detailed clinical records on 3,000 consecutive patients. It’s an amazing and...
In Ductal Carcinoma in Situ, Benefit of Wider Margins Tied to Radiation Use
The relationship between margin width and risk of recurrence after breast-conserving surgery for ductal carcinoma in situ depends on the use of radiation, according to a surgical oncologist who sought to determine the optimal margin width in these patients.1 “Positive margins are associated with an ...
Expert Point of View: Douglas A. Levine, MD
In the discussion session, Douglas A. Levine, MD, Head of Gynecology Research Laboratory at Memorial Sloan Kettering Cancer Center, said that while advanced genomics can help to predict outcomes, stratify treatment, and understand biology, one of the problems of precision medicine is that...
Liquid Biopsies Predict Treatment Response and Survival in Gynecologic Cancers
A new study has demonstrated for the first time that personalized circulating tumor DNA (ctDNA) biomarkers in gynecologic cancers can detect the presence of residual tumor earlier than currently used serum and imaging studies.1,2 According to the data, undetectable levels of ctDNA at the completion ...
Expert Point of View: Kian Behbakht, MD
Kian Behbakht, MD, Professor of Gynecologic Oncology at the University of Colorado School of Medicine, Aurora, said that the study underscored the surgical importance of getting to no visible residual disease in ovarian cancer. “Based on today’s data,” said Dr. Behbakht, “it seems as though it’s...
AACR 2016: Delays in Radiation Therapy Increase Chance of Breast Tumor Development in Women Treated for DCIS
Women who underwent treatment for ductal carcinoma in situ (DCIS) were at higher risk of developing malignant breast tumors if they did not receive timely radiation therapy as part of their treatment, according to a study presented by Liu et al at the 2016 AACR Annual Meeting (Abstract 2576). DCIS ...
AACR 2016: Comparison of Three Different PD-L1 NSCLC Diagnostic Tests Shows a High Degree of Concordance
Three commercially available diagnostic tests were similarly effective in measuring programmed death ligand 1 (PD-L1) protein expression on non–small cell lung cancer (NSCLC) tumor samples, indicating that health-care providers may someday be able to use these tests interchangeably when...
AACR 2016: Certain Oral Bacteria May Be Associated With Increased Pancreatic Cancer Risk
The presence of two species of bacteria linked to periodontal disease in the mouths of healthy individuals was associated with an increased risk of subsequently developing pancreatic cancer, according to research presented by Fan et al at the 2016 AACR Annual Meeting (Abstract 4350). ...
Interim FDG-PET Response-Adapted Therapy May Be of Benefit in Hodgkin Lymphoma
In a phase II US Intergroup trial (Southwest Oncology Group S0816) reported in the Journal of Clinical Oncology, Press et al found that early interim fluorodeoxyglucose positron-emission tomography (FDG-PET) to guide response-adapted therapy resulted in progression-free survival substantially...
ASCO Statement on Human Papillomavirus Vaccination for Cancer Prevention
As reported in the Journal of Clinical Oncology by Bailey et al, ASCO has released a statement on increasing human papillomavirus (HPV) vaccination to prevent HPV-related cancers in the United States. In the United States, HPV is estimated to cause approximately 99.7% of cervical cancers, 60% of...
Dabrafenib Active in BRAF-Mutant Metastatic NSCLC
Planchard et al found that the BRAF kinase inhibitor dabrafenib (Tafinlar) produced responses in previously treated and untreated patients with BRAF-mutant metastatic non–small cell lung cancer (NSCLC), according to a phase II trial reported in The Lancet Oncology. Activating BRAF V600E...
Study Supports Initial Attempt at Debulking Surgery in Stage IIIC Ovarian, Fallopian Tube, and Peritoneal Carcinoma
In a study exploring the effect of primary debulking surgery in women with bulky stage IIIC ovarian, fallopian tube, and primary peritoneal cancers, cytoreduction to no gross residual disease was associated with the best survival outcomes.1 Cytoreduction to 1 to 10 mm of residual disease was also...
Expert Point of View: Kristin Zorn, MD
Kristin Zorn, MD, Associate Professor and Director of Gynecologic Oncology at the University of Arkansas for Medical Sciences, Little Rock, said that the study’s data confirm the importance of other homologous recombination genes in these defects, not just BRCA1 and BRCA2. “I think this really...
Genetic Testing in Women With Ovarian Cancer Helps to Determine Prognosis
A new study suggests that homologous recombination deficiency may have significant prognostic implications for patients with ovarian cancer, highlighting the importance of genetic testing in this population.1 According to the data, patients with ovarian cancer who have mutations in genes affecting...
Physicians as Champions for Quality Improvement
Interest in quality measurement and improvement was once primarily a concern of regulators, insurers, and consumer advocates. Today, quality improvement is front and center in health care—a continuous mission requiring the efforts of everyone on the health-care team. At the recent ASCO Quality Care ...
Benefits and Risks of Transplantation: The Changing Therapeutic Paradigm for Multiple Myeloma
Although high-dose chemotherapy plus autologous transplantation has been a standard of care in the treatment of younger patients with newly diagnosed multiple myeloma, the advent of effective novel agents for the cancer over the past 15 years has raised the question of whether transplantation, with ...
Novel Strategies Emerging for Triple-Negative Breast Cancer
Compelling hypotheses are emerging about the mechanisms driving triple-negative breast cancer, and they are driving drug development in this area, according to Joyce O’Shaughnessy, MD, Celebrating Women Chair of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center. She is also Medical...
AACR 2016: Palbociclib Shows Antiproliferative Activity in Early-Stage Breast Cancer
The molecularly targeted therapeutic palbociclib (Ibrance) was effective in slowing the multiplication of cancer cells in patients diagnosed with early-stage breast cancer who received no prior therapy, according to data from a phase II clinical trial presented by Arnedos et al at the 2016 AACR...
AACR 2016: 5-Year Survival Rates for Patients With Metastatic Melanoma Treated With Nivolumab Much Higher Than Historical Rates
More than a third of metastatic melanoma patients (34%) who received the anti–programmed cell death protein 1 (PD-1) immunotherapeutic nivolumab (Opdivo) in a phase I clinical trial are still alive 5 years after starting treatment, according to research presented by Hodi et al at the 2016...
AACR 2016: Report Identifies Considerations for Alternative Payment Models for Cancer Care
A roundtable convened by the Turning the Tide Against Cancer initiative, composed of a multidisciplinary group of stakeholders, put forth five policy considerations that are critical to ensuring the delivery of high-quality oncology care while supporting innovation. The report was published by...
Family-Focused Therapy Continued Into Bereavement Benefits High-Risk Families
Family-focused grief therapy continued into bereavement reduced the severity of complicated grief and the risk of prolonged grief disorder among high-risk families of dying cancer patients, according to a report by Kissane et in the Journal of Clinical Oncology. Study Details In the trial,...
Pazopanib of Benefit in Imatinib- and Sunitinib-Resistant GIST in French Phase II Trial
In a French phase II trial reported in The Lancet Oncology, Mir et al found that pazopanib (Votrient) plus best supportive care increased progression-free survival vs best supportive care in patients with advanced gastrointestinal stromal tumors (GIST) resistant to imatinib and sunitinib. Study...
CCR2 Inhibitor Active in Combination With FOLFIRINOX in Advanced Pancreatic Cancer
A CCR2 inhibitor (PF-04136309) was active in combination with FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, fluorouracil) in treatment-naive patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma, according to a single-center phase Ib study reported by Nywening...
AACR 2016: MammaPrint Genetic Test Can Reduce Use of Adjuvant Chemotherapy Among Early-Stage Breast Cancer Patients
Among patients with early-stage breast cancer who were considered at high risk for disease recurrence based on clinical and biologic criteria, the MammaPrint genetic test identified a large group of patients for whom 5-year distant metastasis–free survival was equally good whether or not they ...
AACR 2016: LOXO-101 Shows Continued Promise in Patients Whose Tumors Had NTRK Gene Fusions
The investigational drug LOXO-101, which selectively targets a family of proteins called neurotrophic tyrosine kinase receptors (NTRKs), produced significant tumor regression in patients whose tumors had NTRK gene fusions, according to data from a phase I clinical trial presented by Hong et al at...
AACR 2016: RAF-Targeted Therapeutic BGB-283 Shows Early Promise Against Tumors With BRAF and RAS Mutations
The new investigational anticancer therapeutic BGB-283, which targets the RAF family of proteins, was safe, tolerable, and showed signs of clinical activity in patients who had a range of types of cancer with mutations in BRAF, KRAS, and NRAS, according to results from a phase I clinical trial...
ELCC 2016: Studies Confirm Benefit of Plasma Genotyping to Predict Treatment Benefit in Patients With Non–Small Cell Lung Cancer
The benefit of plasma genotyping to predict treatment benefit in patients with non–small cell lung cancer (NSCLC) was confirmed in three studies presented April 15 at the European Lung Cancer Conference (ELCC) 2016 in Geneva. However, researchers warned that plasma tests are unlikely to fully ...
ELCC 2016: Patients With EGFR-Expressing Non–Small Cell Lung Cancer Benefit Most From Necitumumab Added to Chemotherapy
Patients with epidermal growth factor receptor (EGFR)-expressing advanced squamous non–small cell lung cancer benefit most from necitumumab (Portrazza) added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented by Paz-Ares et al (Abstract ...
ASBS 2016: Fertility Counseling in Women of Childbearing Age After Breast Cancer
Despite recent advances in assisted reproductive technology for women with breast cancer, documented fertility counseling at diagnosis remains low, while 89% of those made aware of their options sought specialized consultation for reproductive preservation. Almost 50% of these women chose one of...
Hypofractionated Radiotherapy Not Inferior to Conventional Radiotherapy in Low-Risk Prostate Cancer
Hypofractionated radiotherapy was not inferior to conventional radiotherapy in terms of disease-free survival among men with low-risk prostate cancer, according to the results of the phase III NRG Oncology RTOG 0415 trial reported in the Journal of Clinical Oncology by Lee et al. However, it was...
